FrancophonIA/ELRC3.0 huggingface dataset:
English: In most clinical trials, reduced total plasma triglycerides and free fatty acids, and increased HDL-cholesterol levels were observed as compared to placebo, with small, but not clinically significant increases in LDL-cholesterol levels.
Estonian: Enamustes kliinilistes uuringutes vähenes plasma üldine triglütseriidide ja vabade rasvhapete tase ning tõusis HDL-kolesterooli tase, võrreldes platseeboga, ning LDL-kolesterooli taseme märkimisväärset muutust olid väikesed kuid kliiniliselt vähetähtsad.
English: Glustin 15 mg tablets Glustin 30 mg tablets Glustin 45 mg tablets
Estonian: Glustin 15 mg tabletid Glustin 30 mg tabletid Glustin 45 mg tabletid pioglitasoon
English: 6 In active comparator controlled trials mean weight increase with pioglitazone given as monotherapy was 2-3 kg over one year.
Estonian: 6 Aktiivsetes võrdlevates kontrolluuringutes, kus pioglitasooni anti monoteraapiana, tõusis kehakaal keskmiselt 2...3 kg ühe aasta jooksul.
English: Therapy with pioglitazone should not be initiated in patients with increased baseline liver enzyme levels (ALT >2.5 x upper limit of normal) or with any other evidence of liver disease.
Estonian: Pioglitasoonravi ei tohi alustada neil patsientidel, kellel maksaensüümi väärtused on tõusnud (ALAT > 2,5 korda üle normi) või esineb mõni muu maksahaigusele viitav näitaja.
English: 4 A pooled analysis was conducted of adverse reactions of bone fractures from randomised, comparator controlled, double blind clinical trials in over 8,100 patients in the pioglitazone-treated groups and 7,400 in the comparator-treated groups of up to 3.5 years duration.
Estonian: 4 Luumurdude kõrvaltoimete teadete põhjal viidi läbi ühisanalüüs randomiseeritud, võrdlusravimiga kontrollitud, topelt-pimedad kuni 3,5 aastat kestnud kliinilised uuringud, mis hõlmasid 8100 pioglitasooniga ravitud patsiendigrupi ja 7400 võrdlusravimiga ravitud patsiendigrupi.
English: If you accidentally take too many tablets, or if someone else or a child takes your medicine, talk to a doctor or pharmacist immediately.
Estonian: Kui te kasutate Glustini rohkem kui ette nähtud Informeerige oma arsti või apteekrit koheselt, kui olete kogemata võtnud liiga palju tablette või kui laps või keegi teine on võtnud teie ravimit.
English: Broken bones have been reported commonly (may affect up to 1 in 10 people) in female patients taking Glustin and have also been reported in male patients (frequency cannot be estimated from the available data) taking Glustin.
Estonian: Sageli on teatatud luumurdudest Glustin`i kasutavatel naissoost patsientidel (võib esineda kuni 1-l inimesel 10 -st) ja ka Glustin`i võtvatel meessoost patsientidel (esinemissagedust ei saa hinnata olemasolevate andmete alusel).Kui Teil esineb sellist kõrvaltoimet, võtke võimalikult kiiresti oma arstiga ühendust.
English: common (may affect up to 1 in 10 people) - respiratory infection - abnormal vision - weight gain - numbness uncommon (may affect up to 1 in 100 people) - inflammation of the sinuses (sinusitis) - difficulty sleeping (insomnia)
Estonian: sage (võib esineda kuni 1 inimesel 10-st) hingamisteede põletikud nägemishäire kehakaalu tõus tuimus aeg-ajalt (võib esineda kuni 1 inimesel 100-st) põskkoopapõletik unetus (insomnia)
English: Takeda Pharmaceuticals Slovakia s.r.o.
Estonian: Slove nská re publika Takeda Pharmaceuticals Slovakia s.r.o.
English: Glustin contains pioglitazone.
Estonian: Glustin sisaldab pioglitasooni.
English: How to take Glustin
Estonian: Kuidas Glustini kasutada
English: EU/1/00/151/003 EU/1/00/151/004 EU/1/00/151/005 EU/1/00/151/006 EU/1/00/151/007 EU/1/00/151/008 EU/1/00/151/009 EU/1/00/151/010 EU/1/00/151/011 EU/1/00/151/012 EU/1/00/151/013 EU/1/00/151/014 EU/1/00/151/015 EU/1/00/151/016 EU/1/00/151/017 EU/1/00/151/018 EU/1/00/151/019 EU/1/00/151/020 EU/1/00/151/021 EU/1/00/151/022 EU/1/00/151/023 EU/1/00/151/024
Estonian: EU/1/00/151/001 EU/1/00/151/002 EU/1/00/151/003 EU/1/00/151/004 EU/1/00/151/005 EU/1/00/151/006 EU/1/00/151/007 EU/1/00/151/008 EU/1/00/151/009 EU/1/00/151/010 EU/1/00/151/011 EU/1/00/151/012 EU/1/00/151/013 EU/1/00/151/014 EU/1/00/151/015 EU/1/00/151/016 EU/1/00/151/017 EU/1/00/151/018 EU/1/00/151/019 EU/1/00/151/020 EU/1/00/151/021 EU/1/00/151/022 EU/1/00/151/023 EU/1/00/151/024
English: The other side effects that have been experienced by some patients taking Glustin are:
Estonian: Glustini kasutanud patsientidel esinenud muud kõrvaltoimed hõlmavad järgmist:
English: Metabolism and nutrition disorders hypo-glycaemia uncommon very common common appetite increased uncommon
Estonian: Ainevahetus- ja toitumishäired hüpoglükeemia aeg-ajalt väga sage söögiisu tõus aeg-ajalt
English: Localised swelling (oedema) has also been experienced very commonly (may affect more than 1 in 10 people) in patients taking Glustin in combination with insulin.
Estonian: Glustini koos insuliiniga kasutanud patsientidel on väga sageli (võib esineda rohkem kui 1 inimesel 10 -st) esinenud ka lokaliseeritud paistetust (turse).
English: What you need to know before you take Glustin Do not take Glustin:
Estonian: 2. Mida on vaja teada enne Glustini kasutamist
English: Allergic reactions have been reported with frequency not known (cannot be estimated from the available data) in patients taking Glustin.
Estonian: Glustini kasutavatel patsientidel on teatatud allergilistest reaktsioonidest teadmatasagedusega (ei saa hinnata olemasolevate andmete alusel).
English: A higher rate of fractures was observed in women taking pioglitazone (2.6%) versus comparator (1.7%).
Estonian: Suurem murdude esinemissagedus oli pioglitasooni saanud naistel (2,6%), võrreldes võrdlusravimiga (1,7).
English: Glustin 45 mg tablets
Estonian: Glustin 45 mg tabletid
English: Glustin 30 mg tablets
Estonian: Glustin 30 mg tabletid
English: Glustin 15 mg tablets
Estonian: Glustin 15 mg tabletid
English: Each Glustin 30 mg tablet contains 30 mg of pioglitazone (as hydrochloride).
Estonian: Iga Glustin 30 mg tablett sisaldab 30 mg pioglitasooni (vesinikkloriidina).
English: Bladder cancer has been experienced uncommonly (may affect up to 1 in 100 people) in patients taking Glustin.
Estonian: Glustini kasutanud patsientidel on aeg-ajalt (võib esineda kuni 1 inimesel 100 -st) esinenud põievähki.
English: Each Glustin 45 mg tablet contains 45 mg of pioglitazone (as hydrochloride).
Estonian: Iga Glustin 45 mg tablett sisaldab 45 mg pioglitasooni (vesinikkloriidina).
English: Glustin 30 mg tablets are white to off-white, round, flat tablets marked “30” on one face, “AD4” on the other.
Estonian: Glustin 30 mg tabletid on valged või kahvatuvalged ümmargused lamedad ning ühel küljel on märgistus „30“ teisel küljel on märgistus „AD4“.
English: - Glustin 45 mg tablets are white to off-white, round, flat tablets marked “45” on one face, “AD4” on the other.
Estonian: Glustin 45 mg tabletid on valged või kahvatuvalged ümmargused lamedad ning ühel küljel on märgistus „45“ teisel küljel on märgistus „AD4“.
English: Frequency of adverse reactions of pioglitazone by treatment regimen Monotherapy
Estonian: Pioglitasooni kõrvaltoimete esinemissagedus ravirežiimi järgi
English: The risk of fractures should be considered in the long term care of patients treated with pioglitazone (see section 4.8).
Estonian: Mõned epidemioloogilised uuringud näitasid luumurdude riski sarnast suurenemist nii meestel kui naistel.Pioglitasooniga ravitavatel patsientidel tuleb pikaajalise ravi korral arvesse võtta murdude esinemise riski (vt lõik 4.8).
English: There may be an increased possibility of becoming pregnant because you may ovulate again when you take Glustin.
Estonian: Kui te võtate Glustini, võib teil esineda ovulatsioon, mis suurendab rasestumise võimalust.
English: Your doctor will ask you to have blood tests periodically during treatment with Glustin.
Estonian: Võttes Glustini tablette, palub teie arst teil regulaarsete intervallide tagant anda vereanalüüsi.
English: Each Glustin 15 mg tablet contains 15 mg of pioglitazone (as hydrochloride).
Estonian: Iga Glustin 15 mg tablett sisaldab 15 mg pioglitasooni (vesinikkloriidina).
English: - Glustin 15 mg tablets are white to off-white, round, convex tablets marked “15” on one face, “AD4” on the other.
Estonian: Glustin 15 mg tabletid on valged või kahvatuvalged ümmargused kumerad ning ühel küljel on märgistus „15“ teisel küljel on märgistus „AD4“.
English: Heart failure has been experienced commonly (may affect up to 1 in 10 people) in patients taking Glustin in combination with insulin.
Estonian: Sageli on Glustiniga samal ajal insuliini kasutanud patsientidel esinenud südamepuudulikkust (võib esineda kuni 1 inimesel 10 -st).
English: Package leaflet: Information for the patient Glustin 15 mg tablets
Estonian: RAVIMPREPARAADI NIMETUS Glustin 15 mg tabletid
English: EU/1/00/151/008 14 tablets EU/1/00/151/004 28 tablets EU/1/00/151/017 30 tablets EU/1/00/151/005 50 tablets EU/1/00/151/024 56 tablets EU/1/00/151/018 84 tablets EU/1/00/151/019 90 tablets EU/1/00/151/006 98 tablets
Estonian: EU/1/00/151/008 14 tabletti EU/1/00/151/004 28 tabletti EU/1/00/151/017 30 tabletti EU/1/00/151/005 50 tabletti EU/1/00/151/024 56 tabletti EU/1/00/151/018 84 tabletti EU/1/00/151/019 90 tabletti EU/1/00/151/006 98 tabletti
English: EU/1/00/151/009 14 tablets EU/1/00/151/010 28 tablets EU/1/00/151/020 30 tablets EU/1/00/151/011 50 tablets EU/1/00/151/012 56 tablets EU/1/00/151/021 84 tablets EU/1/00/151/022 90 tablets EU/1/00/151/013 98 tablets
Estonian: EU/1/00/151/009 14 tabletti EU/1/00/151/010 28 tabletti EU/1/00/151/020 30 tabletti EU/1/00/151/011 50 tabletti EU/1/00/151/012 56 tabletti EU/1/00/151/021 84 tabletti EU/1/00/151/022 90 tabletti EU/1/00/151/013 98 tabletti
English: EU/1/00/151/007 14 tablets EU/1/00/151/001 28 tablets EU/1/00/151/014 30 tablets EU/1/00/151/002 50 tablets EU/1/00/151/023 56 tablets EU/1/00/151/015 84 tablets EU/1/00/151/016 90 tablets EU/1/00/151/003 98 tablets
Estonian: EU/1/00/151/007 14 tabletti EU/1/00/151/001 28 tabletti EU/1/00/151/014 30 tabletti EU/1/00/151/002 50 tabletti EU/1/00/151/023 56 tabletti EU/1/00/151/015 84 tabletti EU/1/00/151/016 90 tabletti EU/1/00/151/003 98 tabletti
English: Suomi/Finland
Estonian: Suomi/Finland Takeda Oy
English: Environmental Risk Assessment (ERA) No environmental impact is anticipated from the clinical use of pioglitazone
Estonian: Keskkonnariski hindamine Pioglitasooni kliiniline kasutamine ei avalda mõju keskkonnale.
English: Cardiac disorders heart failure3
Estonian: Südame häired südame-puudulikk us3
English: The tablets are white to off-white, round, flat and marked ‘45' on one face, ‘AD4' on the other.
Estonian: Tabletid on valged või kahvatuvalged ümmargused lamedad ning ühel küljel on märgistus „45“ teisel küljel on märgistus „AD4“.
English: Deutschland
Estonian: Ísland
English: The tablets are white to off-white, round, flat and marked ‘30' on one face, ‘AD4' on the other.
Estonian: Tabletid on valged või kahvatuvalged ümmargused lamedad ning ühel küljel on märgistus „30“ teisel küljel on märgistus „AD4“.
English: ANNEX II A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
Estonian: B. HANKE- JA KASUTUSTINGIMUSED VÕI PIIRANGUD Retseptiravim.
English: The tablets are white to off-white, round, convex and marked ‘15' on one face, ‘AD4' on the other.
Estonian: Tabletid on valged või kahvatuvalged ümmargused kumerad ning ühel küljel on märgistus „15“ teisel küljel on märgistus „AD4“.
English: If you take anti-inflammatory medicines which can also cause fluid retention and swelling, you must also tell your doctor.
Estonian: Kui te võtate põletikuvastaseid ravimeid, mis ka võivad põhjustada vedelikupeetust ja turseid, peate seda samuti oma arstile ütlema; kui teil on spetsiaalset tüüpi diabeetiline silmahaigus, makulaarne ödeem (silma tagaosa turse); kui teil on munasarjatsüstid (polütsüstiliste munasarjade sündroom).
English: However, certain medicines are especially likely to affect the amount of sugar in your blood: - gemfibrozil (used to lower cholesterol) - rifampicin (used to treat tuberculosis and other infections) Tell your doctor or pharmacist if you are taking any of these.
Estonian: rifampitsiin (kasutatakse tuberkuloosi ja teiste infektsioonide raviks).
English: Renal impairment
Estonian: artralgia seljavalu
English: Glustin 45 mg tablets pioglitazone
Estonian: RAVIMPREPARAADI NIMETUS Glustin 45 mg tabletid pioglitasoon
English: Glustin 30 mg tablets pioglitazone
Estonian: RAVIMPREPARAADI NIMETUS Glustin 30 mg tabletid pioglitasoon
English: Neoplasms benign, malignant and unspecified (including cysts and polyps)
Estonian: He a-, pahaloomulised ja täpsustamata kasvajad
English: Blood and lymphatic system disorders anaemia common
Estonian: Vere ja lümfis üs te emi häired aneemia
English: Bladder Cancer
Estonian: KLIINILISED ANDMED
English: 14 January 2013
Estonian: 14. jaanuar 2013
English: The European Commission issued a decision on 14 January 2013.
Estonian: Euroopa Komisjon tegi otsuse 14. jaanuaril 2013.
English: Member States', in this instance Belgium, Bulgaria, Cyprus, Germany, Greece, Malta, Portugal, Romania and United Kingdom).
Estonian: Belgia, Bulgaaria, Kreeka, Küpros, Malta, Portugal, Rumeenia, Saksamaa ja Ühendkuningriik.
English: This could potentially lead to medication errors and pose a risk to public health.
Estonian: See võib põhjustada ravimi manustamise vigu ja ohustada rahvatervist.
English: It controls many body functions, mainly to do with growth and energy.
Estonian: Türoksiin juhib paljusid organismi funktsioone, eelkõige neid, mis on seotud kasvu ja energiavahetusega.
English: EMA/659681/2012 Rev1.
Estonian: EMA/659681/2012 Rev. 1 EMEA/H/A-29/1328
English: • thyroid cancer.
Estonian: • kilpnäärmevähk.
English: Based on evaluation of the currently available data and the scientific discussion within the Committee, the CHMP agreed that there was a risk that the dropper used for delivery might deliver variable doses, and that large numbers of drops might be hard to count.
Estonian: Tuginedes olemasolevate andmete hindamisele ja komiteesisesele teaduslikule arutelule, järeldas inimravimite komitee, et on olemas risk, et ravimi manustamiseks kasutatava tilgutiga võidakse välja mõõta varieeruvaid annuseid ning suurt arvu tilku võib olla keerukas loendada.
English: However, the Member States were not able to reach an agreement and the Dutch agency referred the matter to the CHMP for arbitration on 26 January 2012.
Estonian: Liikmesriigid ei jõudnud aga menetluse käigus üksmeelele ja Madalmaade ravimiamet tegi 26. jaanuaril 2012 inimravimite komiteele vahekohtumenetluse alustamise esildise.
English: Why was Levothyroxine Alapis reviewed?
Estonian: Miks Levothyroxine Alapis üle vaadati?
English: On 18 October 2012, the European Medicines Agency completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Levothyroxine Alapis.
Estonian: Euroopa Ravimiamet (EMA) lõpetas 18. oktoobril 2012 vahekohtumenetluse, mis algatati pärast seda, kui Euroopa Liidu liikmesriigid ei jõudnud kokkuleppele ravimi Levothyroxine Alapis heakskiitmises.
English: In addition there were concerns over the safety of the combined long-term use of the ingredients ethanol and propylene glycol at the proposed concentrations, particularly in children.
Estonian: Samuti tekitas küsimusi koostisainete etanooli ja propüleenglükooli kombineeritud pikaajalise kasutamise ohutus kavatsetud kontsentratsioonide korral, eriti lastel.
English: It was to be available as oral drops (100 microgram/ml).
Estonian: Ravimit kavatseti turustada suukaudsete tilkadena (100 μg/ml).
English: What is Levothyroxine Alapis?
Estonian: Mis on Levothyroxine Alapis?
English: Alapis S.A. submitted an application for Levothyroxine Alapis to the Dutch medicines regulatory agency for a decentralised procedure.
Estonian: Alapis S.A. esitas Madalmaade ravimiametile Levothyroxine Alapise detsentraliseeritud menetlusega heakskiitmise taotluse.
English: In addition, there remained concern over the safety of the long-term use of the ingredients ethanol and propylene glycol in children, and some groups of adults such as those with alcoholism.
Estonian: Samuti jäi lahendamata koostisainete etanooli ja propüleenglükooli kombineeritud pikaajalise kasutamise ohutuse küsimus lastel ja teatud täiskasvanurühmades, näiteks alkoholismi korral.
English: Therefore the CHMP concluded that the benefits of Levothyroxine Alapis do not outweigh its risks, and that the marketing authorisation should not be granted in the concerned Member States.
Estonian: Seetõttu järeldas inimravimite komitee, et Levothyroxine Alapise kasulikkus ei ole suurem kui sellega kaasnevad riskid, ning soovitas asjaomastes liikmesriikides müügiluba mitte anda.
English: Since the solution is highly concentrated and the active substance highly potent, there was an unacceptable risk of serious medication errors.
Estonian: Lahus on väga kontsentreeritud ja ravimi toimeaine on väga tugeva toimega ning see võib põhjustada ravimi manustamise raskete vigade lubamatu riski.
English: Levothyroxine Alapis was intended to be used to treat:
Estonian: Levothyroxine Alapist kavatseti kasutada järgmiste näidustuste korral:
English: The grounds for the referral were concerns raised by the UK related to the dropper insert as a proposed administration device, due to the large number of drops that may be required and concerns about its accuracy in delivering the required dose.
Estonian: Esildise põhjus oli Ühendkuningriigi tõstatatud probleem seoses pakendis oleva tilgutiga, mida kavatseti kasutada ravimi manustamisvahendina, sest ravimi annustamiseks võib olla vaja manustada palju tilku ja seetõttu ei saa olla kindel, et mõõdetav annus oleks täpne.
English: The active substance in Levothyroxine Alapis, levothyroxine sodium, is a synthetic form of the hormone thyroxine.
Estonian: Levothyroxine Alapise toimeaine naatriumlevotüroksiin on hormooni türoksiini sünteetiline vorm.
English: Levothryoxine Alapis is a medicine that contains the active substance levothyroxine sodium.
Estonian: Levothyroxine Alapis on ravim, mis sisaldab toimeainena naatriumlevotüroksiini.
English: • a condition known as Hashimoto's thyroiditis, in which the immune system (the body's natural defences) attacks the thyroid causing it to swell and preventing it from working properly;
Estonian: • Hashimoto türeoidiit ehk seisund, kus immuunsüsteem (organismi looduslik kaitsemehhanism)
English: • conditions in which the thyroid gland is underactive (hypothyroidism, including diffuse non-toxic goitre) and so does not make enough thyroxine for the body's needs;
Estonian: • kilpnäärme vaegtalitlus (hüpotüreoos, sealhulgas difuusne mittetoksiline struuma) ehk seisundid,
English: Thyroxine is normally produced in the body by the thyroid gland in the neck.
Estonian: Türoksiin tekib organismis kaelapiirkonnas asuvas kilpnäärmes.
English: This is a procedure where one Member State (the ‘reference Member State', in this instance the Netherlands) assesses a medicine with a view to granting a marketing authorisation that will be valid in this country as well as in other Member States (the ‘concerned
Estonian: See on menetlus, kus üks liikmesriik (viiteliikmesriik, praegusel juhul Madalmaad) hindab ravimit, et otsustada, kas anda ravimi müügiluba, mis kehtib selles riigis ja teistes liikmesriikides (asjaomased liikmesriigid, praegusel juhul Belgia, Bulgaaria, Kreeka, Küpros, Malta, Portugal, Rumeenia, Saksamaa ja Ühendkuningriik).
English: 56 capsules
Estonian: 56 kapslit
English: 30 mg Capsule, hard Oral use bottle (HDPE)
Estonian: Pudel (HDPE)
English: Pack size
Estonian: Suukaudne
English: This summary was last updated in 07-2012.
Estonian: Kokkuvõtte viimane uuendus: 07-2012.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Doribax on 25 July 2008.
Estonian: Euroopa Komisjon andis Doribaxi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 25. Juulil 2008.
English: The standard dose of Doribax is 500 mg every eight hours.
Estonian: Doribaxi tavaannus on 500 mg iga 8 tunni järel.
English: It is used to treat the following infections in adults:
Estonian: Seda kasutatakse täiskasvanutel järgmiste infektsioonide raviks:
English: ‘Complicated' means that the infection is difficult to treat;
Estonian: Tüsistunud tähendab, et infektsiooni on raske ravida.
English: Each infusion lasts for one hour, although some patients with nosocomial pneumonia may need infusions lasting four hours.
Estonian: Iga infusioon kestab 1 tunni, kuigi mõni nosokomiaalse pneumooniaga patsient võib vajada 4 tundi kestvat infusiooni.
English: The full EPAR for Doribax can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Doribaxi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: In all of the studies, the main measure of effectiveness was the number of patients whose infection
Estonian: Kõigis uuringutes oli efektiivsuse põhinäitaja patsientide arv, kelle infektsioon oli ravi järel paranenud.
English: The most common side effect with Doribax (seen in more than 1 patient in 10) is headache.
Estonian: Doribaxi kõige sagedam kõrvalnäht (esinenud enam kui 1 patsiendil 10st) on peavalu.
English: Before using Doribax, doctors should consider official guidance on the use of antibiotics.
Estonian: Enne Doribaxi kasutamist peab arst arvesse võtma antibiootikumide kasutamise ametlikke suuniseid.
English: The CHMP decided that Doribax's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Doribaxi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Treatment usually continues for between five and 14 days, depending on the type and severity of the infection and the patient's response (10 to 14 days are usually needed in nosocomial pneumonia).
Estonian: Ravi kestus on olenevalt infektsiooni tüübist ja raskusest ning patsiendi ravivastusest 5-14 päeva (nosokomiaalse pneumoonia korral tavaliselt 10-14 päeva).
English: It works by attaching to certain types of protein on the surface of the bacteria cells.
Estonian: Toimeaine seondub teatud liiki valkudega bakterite pinnal.
English: Other information about Doribax
Estonian: Muu teave Doribaxi kohta
English: Doribax was as effective as the other antibiotics in treating the infections:
Estonian: Doribax oli infektsioonide ravimisel sama tõhus kui teised antibiootikumid:
English: • nosocomial pneumonia (an infection of the lungs).
Estonian: • Nosokomiaalne pneumoonia (kopsupõletik).
English: This is a summary of the European public assessment report (EPAR) for Doribax.
Estonian: See on ravimi Doribax Euroopa avaliku hindamisaruande kokkuvõte.
English: For more information about treatment with Doribax, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Doribaxiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Doribax is an antibiotic.
Estonian: Doribax on antibiootikum.
English: This prevents the bacteria from building the walls that surround their cells, which kills the bacteria.
Estonian: See takistab bakteriraku membraani moodustamist, hävitades bakterid.
English: It must not be used in patients who are severely allergic to other ‘beta-lactam' antibiotics, such as penicillins or cephalosporins.
Estonian: Dorbaxi ei tohi kasutada patsientidel, kellel on tugev allergia muude beetalaktaamantibiootikumide, näiteks penitsilliinide või tsefalosporiinide suhtes.
English: Why has Doribax been approved?
Estonian: Miks Doribax heaks kiideti?
English: Doribax is a medicine containing the active substance doripenem.
Estonian: Doribax on ravim, mis sisaldab toimeainena doripeneemi.
English: What is the risk associated with Doribax?
Estonian: Mis riskid Doribaxiga kaasnevad?